In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galenica Group buys Aspreva for $915mm

Executive Summary

Switzerland's Galenica Group (manufactures and sells nephrology drugs, runs pharmacies, and has a logistics/health care information business) has agreed to pay $915mm in cash ($26 per share; a 19% premium) to acquire Aspreva (autoimmune disease therapeutics).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition

Related Companies